Verona Pharma has announced new collaborations with two European technology companies to develop its first-in-class product candidate RPL554 as dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for maintenance treatment of chronic obstructive pulmonary disease (COPD).
Clinical-stage immuno-oncology firm Agenus is reorganizing its business and operations to straighten its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program.
Warp Drive Bio has partnered with GSK to discover potential therapeutics in oncology and other diseases.
University of Dundee in the UK has been awarded almost £1m to boost efforts to identify new new antibiotics to tackle bacterial infections.
PureTech Health has signed a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
Clinical-stage biopharmaceutical firm BioLineRx has purchased Agalimmune, a private UK-based company with an anti-cancer immunotherapy platform.
Regeneron Pharmaceuticals announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource.
SalvaRx, a subsidiary of SalvaRx Group, has agreed to invest in Delaware-based biotechnology company Rift Biotherapeutics which focuses on the development of antibodies for use in oncology.
Cellular immunotherapy company, Cell Medica has secured £60m in a Series C financing round with participation from existing investors Touchstone Innovations, funds managed by Woodford Investment Management, and funds managed by Invesco Perpetual.
PTC Therapeutics has agreed to acquire all rights to Emflaza (deflazacort) from Marathon Pharmaceuticals.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.